Wedbush reiterates Outperform rating on Telix Pharmaceuticals, $22 price target
Wedbush maintained an Outperform rating and $22 price target for Telix Pharmaceuticals, implying a 51.5% upside from its Oct 21 close. The company reported a 19% YoY revenue increase to $245M in Q3 2026 and reaffirmed FY26 revenue guidance exceeding $1B. Strategic partnerships and pipeline expansion were also highlighted.
How this was made
The 30-second read
Why it matters
The analyst note provides a concrete new target and rating, offering a clear short‑term trading signal.
Market read
Analyst upgrade with a sizable price target increase can drive immediate buying interest, especially in a high‑growth biotech.
What to watch
Potential regulatory hurdles for the merger and the need for sustained demand for isotope products.
Background
Wedbush's reiteration of an Outperform rating follows Telix's Q3 revenue growth and guidance for FY26 revenue above $1 billion.
Ticker impact
Wedbush reiterated an Outperform rating on Telix Pharmaceuticals and raised its price target to $22, implying a 51.5% upside from the recent close.
likely upward pressure as investors price in the new $22 target
The rating change is a fresh analyst action with a specific price target, providing a clear catalyst for short‑term buying.
Market effects
May lift sentiment in the radiopharmaceutical and broader biotech sector.
Limited to U.S. biotech investors.
Modest, primarily affecting Telix shareholders and sector peers.
Counterpoint
The price target may be overly optimistic given execution risk of the merger and partnership.
Key entities
- CompanyTelix Pharmaceuticals
U.S.-listed radiopharmaceutical developer (ticker TLX).
- AnalystWedbush Securities
Equity research firm issuing the rating and price target.
